Leadership
Led by an entrepreneurial and experienced management team, supported by a distinguished Board of Directors and a world-class Scientific Advisory Board
Executive team
-
Dr James McIlroy
MBChB, BMedSci (Hons)
CEO & BOARD MEMBER
Qualified medical doctor. Formed company, raised ~£55m, established technology platforms, initiated and completed Ph2 clinical trials with positive data
-
Dr James Barnes
PhD
COO
~20 years of strategic leadership, drug development & business operations. Previously worked as COO at BerGenBio ASA
-
Melissa Strange
FCCA, MBA, LLB (Hons)
CFO
>15 years strategic financial leadership experience in drug development. Actively involved in raising $100m for private and public companies
Board of Directors
-
Elmar Schnee
Non-Executive Chairman
Previously CEO of Merck Serono. Highly experienced Board Chairman in drug development companies
-
Iain Baird
Investor Director
Principal, Development Solutions. >35 years of operational and leadership experience in the pharma industry
-
Mark Bamforth
Investor Director
Founder and CEO of ArrantaBio (acquired by Recipharm), Brammer Bio (acquired by Thermofisher)
-
Douglas Thomson
Investor Director
CEO and co-founder at Pneumagen Limited, a clinical phase anti-infective company
IBS Scientific Advisory Board
-
Professor William D. Chey
Professor of Medicine, Division of Gastroenterology
University of Michigan Health System, Ann Arbor, USA -
Professor Eamonn M. M. Quigley
Chief, Division of Gastroenterology & Hepatology
Houston Methodist Hospital; Professor of Medicine,
Weill Cornell Medical College, USA -
Professor Robin Spiller
Professor of Gastroenterology University of Nottingham, UK
-
Professor Jan Tack
Chairman, Division of Gastroenterology & Hepatology
University Hospitals Leuven; Professor of Internal Medicine,
University of Leuven, Belgium -
Professor Yan Yiannakou
Consultant Neurogastroenterologist & Director of R&D
County Durham & Darlington NHS Foundation Trust, UK
Find out more about our donor programme. Visit Number2.org